Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Thomas Buroker (NPI 1982665337)

Field	Value
Entity Type	Individual
Organization	Thomas Buroker
Address	1950 Sw Magazine Rd
City	Ankeny
State	IA
ZIP	50023
Taxonomy	Medical Oncology Physician
NPI Enumerated	March 28, 2006

Payer Source	Total Paid
Medicare	$9.4M
Medicaid	$0

Key Findings

This provider’s Medicare business is sizable: reported Total Medicare revenue is $9.4M and there is no Medicaid billing on file, so the practice is effectively single‑payer in the dataset and dependent on Medicare for its reported volumes and revenue. The absence of Medicaid activity suggests limited engagement with Medicaid populations or that such services are billed under a different NPI/group not shown here.

Revenue is highly concentrated in a few high-cost oncology drugs: the precomputed top‑3 Medicare codes (J9271, J9144, J9299) account for 67.5% of this provider’s total Medicare revenue. Those three codes correspond to pembrolizumab, daratumumab, and nivolumab—immunotherapy/monoclonal antibody oncology agents—indicating that these therapies are the core revenue drivers rather than a broad mix of lower‑cost services.

J9271 is an extreme national outlier and the single largest contributor to the provider’s Medicare revenue: it generated $3.9M and represents 42.6% of the provider’s Medicare revenue, ranking #1 of 1841 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code). This dominance on a single high‑cost immunotherapy product is a defining feature of the billing profile and explains most of the concentration noted above.

The provider also shows very high relative volume on additional oncology biologics: J9144 produced $1.2M (13.0% of Medicare revenue) and ranks #13 of 615 providers nationally (98th percentile; extreme outlier), while J9299 produced $1.1M (11.9% of Medicare revenue) and ranks #22 of 505 (96th percentile; notably above typical national volume). Together these ranks indicate the provider is a major national participant for multiple high‑cost immune/antibody therapies rather than appearing as a modest local biller.

Procedure and administration codes support an infusion‑center model: high ranks and flagged outlier status on administration/chemotherapy codes such as 96413 ($151.9K; ranks #9 of 7514, 100th percentile; extreme outlier) and 96417 ($20.3K; ranks #13 of 3014, 100th percentile; extreme outlier) point to frequent chemotherapy/infusion sessions. Additional infusion items (96365, 96367) and supportive drug codes (J0185 aprepitant; J2506 pegfilgrastim) appear in the top codes list, reinforcing that the operation centers on in‑office IV/SC oncology treatment and supportive care.

Outpatient evaluation volumes are also notable and suggest substantial follow‑up and management: E/M codes 99215 ($104.4K) and 99214 ($76.7K) are present in the top codes, with 99215 ranked #459 of 145531 providers nationally (100th percentile; extreme outlier) and 99214 in the 97th percentile (notably above typical national volume). These E/M patterns indicate a significant share of high‑complexity outpatient visits alongside infusion services, consistent with medical oncology practice management of complex patients.

Competitive positioning is uneven but strong in niche areas: the provider holds #1 rankings for both J9271 and Q5112 (Q5112 $174.7K; ranks #1 of 6 providers nationally, 100th percentile; typical, unremarkable volume for this code), and top‑tier ranks for multiple other biologic and administration codes. Several codes are flagged as “extreme outlier” or “notably above typical national volume,” which collectively show nationally dominant activity for specific oncology therapies rather than broad dominance across all oncology services.

Tenure is long enough to indicate established practice continuity: the NPI was enumerated on 2006-03-28 (~20 years ago), so the billing pattern reflects an experienced provider with a prolonged presence in Medicare billing. Given the concentration in high‑cost oncology biologics and consistent high ranks across infusion and E/M codes, the provider appears to operate a sustained, infusion‑focused oncology service line over many years.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

89 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	92,400	$40	$3.9M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	31,140	$40	$1.2M
J9299	Injection, nivolumab, 1 mg	45,280	$20	$1.1M
J9173	Injection, durvalumab, 10 mg	7,910	$60	$490.4K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	12,940	$40	$465.8K
J1930	Injection, lanreotide, 1 mg	8,640	$40	$380.2K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	3,490	$50	$181.5K
J0897	Injection, denosumab, 1 mg	9,900	$20	$178.2K
Q5112	Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg	4,480	$40	$174.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,630	$90	$151.9K

Showing 1–10 of 89

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 89 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Thomas Buroker — 18 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

89 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	30	17,200	$40	$902.3K
J9299	1	10	18,700	$20	$527.6K
J9173	1	10	7,910	$60	$491.3K
J9144	1	10	9,900	$40	$476.8K
J1930	1	10	8,640	$40	$379.9K
Q5112	1	10	4,000	$40	$155.6K
Q5126	1	10	3,270	$50	$146.6K
Q5118	1	10	5,840	$20	$137.4K
J1569	1	10	2,680	$40	$133.6K
J9264	1	10	13,700	$10	$133.2K

Showing 1–10 of 89

Related Providers

Other providers that share a Tax Identification Number (TIN) with Thomas Buroker, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Broadlawns Medical Center	IA	General Acute Care Hospital	$0	$112.9M
State University Of Iowa	IA	Family Medicine Physician	$0	$103.8M
State University Of Iowa	IA	General Acute Care Hospital	$0	$90.4M
Catholic Health Initiatives-iowa Corp	IA	General Acute Care Hospital	$0	$26.4M
State University Of Iowa	IA	Dentist	$0	$25.8M
Broadlawns Medical Center	IA	Community/Behavioral Health Agency	$0	$13.2M
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Lucas County Health Center	IA	Rural Health Clinic/Center	$0	$8.1M
Catholic Health Initiatives-iowa Corp	IA	Clinical Medical Laboratory	$0	$8M

Nearby Providers

Other providers in the same ZIP code as Thomas Buroker, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ankeny Csd	IA	Local Education Agency (LEA)	$0	$15.5M
Peacetree Community Living LLC	IA	Assisted Living Facility (Mental Illness)	$0	$4.7M
City Of Ankeny	IA	Land Ambulance	$528.6K	$3.3M
Tandem Services	IA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$3.3M
Jerad Hintz	IA	Dentist	$0	$3M
On With Life, Inc.	IA	Community/Behavioral Health Agency	$0	$2.8M
V And D Leasing, Lc	IA	Taxi	$0	$2M
Norse Ventures	IA	Case Manager/Care Coordinator	$0	$1.6M
Jameson Klavins	IA	Dentist	$0	$1.5M
New Horizons Adult Day Center	IA	Adult Day Care Clinic/Center	$0	$1.1M

Thomas Buroker — Billing Profile & Reimbursement Data

Sign up for Thomas Buroker — Billing Profile & Reimbursement Data policy alerts

Thomas Buroker — Billing Profile & Reimbursement Data

Sign up for Thomas Buroker — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References